ClinicalTrials.gg
CompletedNCT05882318ESSENCEUpdated Nov 3, 2025Results posted

Effectiveness of eCoin at Sensory and Subsensory Amplitudes

An interventional study of eCoin Peripheral Neurostimulator System in Urge Incontinence, sponsored by Valencia Technologies Corporation. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-03.

Sponsored by Valencia Technologies Corporation · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 135 studies in Urinary Incontinence, Urge with a site in United States — 19 open to participants now, 26 under way, none of them phase 3. Urinary Incontinence, Urge · United States.

Enrollment
78th of 119
38 · median 75
Started
2023
with 6 others
No phase
72 of 135
10 open now
Registered
114th of 135
by date
Lead sponsor
4 of 135
Valencia Technologies Corporation

Among the 135 studies in Urinary Incontinence, Urge with a site in United States, this one is the 78th largest by enrollment of the 119 interventional ones that give a count, is one of 7 that started in 2023, is one of 72 with no phase, and was the 114th registered.

Urinary Incontinence, Urge

243 studies on the registry are indexed under Urinary Incontinence, Urge; 39 are open to participants now.

Browse Urinary Incontinence, Urge studies →

Open to participants now

19 of the 135 studies in Urinary Incontinence, Urge with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Urinary Incontinence, Urge studies recruiting now, 18 (72%) set no upper age limit and 2 (8%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 135 studies in Urinary Incontinence, Urge with a site in United States, or all of them as a file.
02

Study summary

The goal of this prospective, multi-center, double-blinded randomized controlled is to learn about effectiveness and QOL with eCoin at two different amplitude settings in subjects with urge urinary incontincence (UUI). The main question it aims to answer is:

  • The reduction in UUI episodes per day on a 3-day voiding diary in both groups after 3 months of therapy

Participants will be implanted with the eCoin device and randomized to either a sensory or subsensory stimulation group and complete voiding diaries and patient reported-outcomes through 3 months of therapy. After 3 months, subjects will be unblinded and reprogramming will be offered. Subjects will be followed for an additional month to a total of 4 months.

03

Conditions studied

  • Urge Incontinence

Keywords

  • Neuromodulation
  • eCoin device
  • Stimulation
  • Tibial nerve
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Individual with diagnosis of overactive bladder with urgency urinary incontinence - daily UUI with a predominantly urgency component
  2. Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or who have undergone percutaneous tibial nerve stimulation (PTNS).
  3. Individual is determined to be a suitable surgical candidate by physician.

Key Exclusion Criteria:

  1. Individual is not appropriate for eCoin therapy based upon the US FDA-approved IFU requirements.
  2. Individual has predominantly stress urinary incontinence (greater than 1/3 of leaks on baseline diary are stress).
  3. Individual has bladder outlet obstruction.
  4. Individual has an active urinary tract infection at time of enrollment or has had four or more symptomatic UTI's in the last 12 months.
  5. Individual has significant lower urinary tract pain or has been diagnosed with interstitial cystitis or bladder pain syndrome that is actively being managed.
  6. Individual has post void residual greater than 200 cc.
  7. Individual has an active diagnosis of bladder, urethral, or prostate cancer.
  8. Individual has had a prior anti-stress incontinence surgery within the last year.
  9. Individual has uncontrolled diabetes mellitus (>7).
  10. Individual is neutropenic or immune-compromised.
  11. Individual has lower extremity pathology such as:

    1. Previous surgery and/or significant scarring at the planned implant location
    2. Ongoing dermatologic condition at the implant site, including but not limited to dermatitis and disorders
    3. Clinically significant peripheral neuropathy in the lower extremities
    4. Pitting edema at the implant location (≥ 2+ is excluded)
    5. Inadequate skin integrity or any evidence of an infection or inflammation in either lower leg
    6. Moderate to severe varicose veins
    7. Open wounds or recent trauma
    8. Arterial and/or vasculitis disease in the lower extremities
    9. Chronic venous insufficiency with a history of skin change (hyperpigmentation, lipodermatosclerosis, ulceration) in the ankle region
  12. Individual has neurogenic bladder dysfunction.
  13. Individual is aware that he or she will need an MRI scan other than a head/neck/shoulder MRI during the study period.
  14. Any condition that, in the investigator's opinion, would preclude participation in the study (e.g., comorbidity that places subject at increased risk for surgical intervention, medical condition that may increase the risk associated with study participation or may interfere with interpretation of study results, inability to adhere to the visit schedule, such as morbid obesity, clotting or bleeding disorder)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Sensory

    Participants in the sensory treatment arm will be programmed to their sensory threshold.

    Device: eCoin Peripheral Neurostimulator System

  • Experimental
    Subsensory

    Participants in the subsensory treatment arm will be programmed to approximately 75% of their sensory threshold.

    Device: eCoin Peripheral Neurostimulator System

Interventions

  • DeviceeCoin Peripheral Neurostimulator System

    The eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management.

06

What researchers measure

Primary outcomes

  1. Change in UUI Episodes Per Day

    The primary endpoint is to explore the effect of two different eCoin amplitude settings on the change of UUI episodes per day on a 3-day voiding diary. A negative number shows a reduction in UUI episodes per day which means symptoms have improved since baseline. A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.

    Time frame: 3 months post-activation

Secondary outcomes

  1. Change in UUI Episodes Per Day

    Change in the number of urgency urinary incontinence episodes per day on a 3-day voiding diary. A negative number shows a reduction in UUI episodes which means symptoms have improved since baseline. A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.

    Time frame: 2 months post-activation

  2. Change in UUI Episodes Per Day

    A secondary endpoint is to explore the change in UUI episodes per day on a 3-day voiding diary. A negative number shows a reduction in UUI episodes per day which means symptoms have improved since baseline. A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.

    Time frame: 4 months post-activation

  3. Change in Overactive Bladder Health Related Quality of Life (HRQL)

    Change from baseline in the patient reported quality of life as assessed by the Health Related Quality of Life (HRQL) portion of the Overactive Bladder questionnaire (OABq) survey. Higher scores on the HRQL portion indicate better quality of life. The maximum HRQL domain score is 100 (best) and the minimum HRQL score is 0 (worst). A positive change in score indicates an improvement in quality of life.

    Time frame: 2 and 3 months post-activation

  4. Change in Overactive Bladder Health Related Quality of Life (HRQL)

    Change from baseline in patient reported quality of life as assessed by the Health Related Quality of Life (HRQL) portion of the Overactive Bladder questionnaire (OABq) survey. Higher scores on the HRQL indicate better quality of life. The maximum HRQL domain score is 100 (best) and the minimum HRQL score is 0 (worst). A positive change in score indicates an improvement in quality of life.

    Time frame: 4 months post-activation

07

Results

Posted Nov 3, 2025

Participant flow

Participant flow — Overall Study
MilestoneSensorySubsensory
Started1818
Completed1717
Not completed11
Withdrew: Withdrawal by subject10
Withdrew: Protocol violation01

Outcome measures

PrimaryChange in UUI Episodes Per Day

The primary endpoint is to explore the effect of two different eCoin amplitude settings on the change of UUI episodes per day on a 3-day voiding diary. A negative number shows a reduction in UUI episodes per day which means symptoms have improved since baseline. A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.

Time frame:
3 months post-activation
Reported as:
Mean · UUI episodes per day
Change in UUI Episodes Per Day
UUI episodes per daySensorySubsensory
Change in UUI Episodes Per Day-2.1 ± 2.42-2.73 ± 1.8
SecondaryChange in UUI Episodes Per Day

Change in the number of urgency urinary incontinence episodes per day on a 3-day voiding diary. A negative number shows a reduction in UUI episodes which means symptoms have improved since baseline. A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.

Time frame:
2 months post-activation
Reported as:
Mean · UUI episodes per day
Change in UUI Episodes Per Day
UUI episodes per daySensorySubsensory
Change in UUI Episodes Per Day-2.75 ± 1.9-2.14 ± 2.58
SecondaryChange in UUI Episodes Per Day

A secondary endpoint is to explore the change in UUI episodes per day on a 3-day voiding diary. A negative number shows a reduction in UUI episodes per day which means symptoms have improved since baseline. A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.

Time frame:
4 months post-activation
Reported as:
Mean · UUI episodes per day
Change in UUI Episodes Per Day
UUI episodes per daySensorySubsensory
Change in UUI Episodes Per Day-2.59 ± 2.6-2.96 ± 2.12
SecondaryChange in Overactive Bladder Health Related Quality of Life (HRQL)

Change from baseline in the patient reported quality of life as assessed by the Health Related Quality of Life (HRQL) portion of the Overactive Bladder questionnaire (OABq) survey. Higher scores on the HRQL portion indicate better quality of life. The maximum HRQL domain score is 100 (best) and the minimum HRQL score is 0 (worst). A positive change in score indicates an improvement in quality of life.

Time frame:
2 and 3 months post-activation
Reported as:
Mean · Change in HRQL Score
Change in Overactive Bladder Health Related Quality of Life (HRQL)
Change in HRQL ScoreSensorySubsensory
2 months25.87 ± 21.622.78 ± 24.19
3-months18.15 ± 22.6322.59 ± 24.95
SecondaryChange in Overactive Bladder Health Related Quality of Life (HRQL)

Change from baseline in patient reported quality of life as assessed by the Health Related Quality of Life (HRQL) portion of the Overactive Bladder questionnaire (OABq) survey. Higher scores on the HRQL indicate better quality of life. The maximum HRQL domain score is 100 (best) and the minimum HRQL score is 0 (worst). A positive change in score indicates an improvement in quality of life.

Time frame:
4 months post-activation
Reported as:
Mean · Change in HRQL Score
Change in Overactive Bladder Health Related Quality of Life (HRQL)
Change in HRQL ScoreSensorySubsensory
Change in Overactive Bladder Health Related Quality of Life (HRQL)22.03 ± 25.5632.09 ± 26.2

Adverse events

Collected over 4 months post-activation. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sensory0/18 (0%)0/18 (0%)7/18 (38.9%)
Subsensory0/18 (0%)0/18 (0%)6/18 (33.3%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventSensorySubsensory
Incision Site Impaired HealingInjury, poisoning and procedural complications2/180/18
Site Incision PainInjury, poisoning and procedural complications2/180/18
Medical Device Site ErythemaGeneral disorders0/181/18
Post Procedural DiscomfortGeneral disorders0/181/18
Incision Site DischargeInjury, poisoning and procedural complications1/180/18
Implant Site OedemaInjury, poisoning and procedural complications1/181/18
Incision Site HaemorrhageInjury, poisoning and procedural complications0/181/18
Incision Site Cellulitis, Medical Device Site CellulitisInfections and infestations1/180/18
Postoperative Wound InfectionInjury, poisoning and procedural complications0/181/18
Incision Site Pain, Implant Site BruisingInjury, poisoning and procedural complications0/181/18

Baseline characteristics

The number of baseline participants refers to the number of participants who were implanted and randomized into a study arm.

Age, Continuous
Age, Continuous(years)SensorySubsensoryTotal
Mean66 ± 1365 ± 1466 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)SensorySubsensoryTotal
Female161632
Male224
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SensorySubsensoryTotal
Hispanic or Latino011
Not Hispanic or Latino181533
Unknown or Not Reported022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SensorySubsensoryTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American011
White171532
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)SensorySubsensoryTotal
United States181830
Smoking Status, Current Smoker
Smoking Status, Current Smoker(Participants)SensorySubsensoryTotal
Count of participants000
Baseline UUI Episodes per Day
Baseline UUI Episodes per Day(UUI Episodes per day)SensorySubsensoryTotal
Mean4.91 ± 2.125.9 ± 3.015.39 ± 2.6
Baseline HRQL Score
Baseline HRQL Score(HRQL Score)SensorySubsensoryTotal
Mean53.07 ± 18.6753.13 ± 22.1353.1 ± 20.11
08

Study locations

7 sites
  • Genesis Research
    Downey, California 90241, United States
  • Urology Associates of Central California
    Fresno, California 93720, United States
  • The Iowa Clinic
    Ankeny, Iowa 50023, United States
  • Cypress Medical Research Center
    Wichita, Kansas 67226, United States
  • Adult & Pediatric Urology P.C.
    Omaha, Nebraska 68114, United States
  • Associated Urologists of North Carolina
    Raleigh, North Carolina 27612, United States
  • Institute for Female Pelvic Medicine
    Allentown, Pennsylvania 18103, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Apr 2024, 10 months.

Results were first posted in Nov 2025, 1 year 6 months after primary completion.

Of 77 interventional studies with no phase under Urinary Incontinence, Urge, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
May 31, 2023
StartActual
Jun 6, 2023
Primary completionActual
Apr 19, 2024
CompletionActual
May 14, 2024
Results first posted
Nov 3, 2025
Last update
Nov 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05882318
Lead sponsor
Valencia Technologies Corporation
Responsible party
Sponsor
First posted
May 31, 2023
Start date
Jun 6, 2023
Primary completion
Apr 19, 2024
Completion
May 14, 2024
Results posted
Nov 3, 2025
Last update
Nov 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion